Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

NCT00931372 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication lixisenatide can help restore insulin release in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 22 people

Who can join Ages 18–65 · all sexes

Timeline Started 2009-06 · est. completion 2009-08

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT00931372 ↗

Description as written by the study sponsor.

The objective of this study is to test whether Lixisenatide (AVE0010) restores first phase and improves second phase insulin response in subjects with diabetes mellitus type 2.

Treatments tested

Lixisenatide (AVE0010) Drug

Solution for subcutaneous injection 100 µg/mL
Placebo Drug

Subcutaneous injection

Main thing measured	Area under the insulin secretion curve
Sponsor	Sanofi
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	lixisenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00931372 ↗